The company focuses on therapeutic areas such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. 2026 is a pivotal year for Novartis as it navigates the largest patent expiry in its history. The company maintains strong margins around 40% and continues investing heavily in pipeline development with key growth drivers offsetting generic erosion.
Cyborg Score Rationale
The company demonstrates strong profitability with an operating margin of 31.09% and net margin of 25.44%. However, 2026 represents a transition year amid significant patent expirations and generic competition headwinds, particularly for key drugs like Entresto and Promacta.
Top Insights
2026 is a pivotal year navigating the largest patent expiry in its history, with Q4 revenues missing estimates amid generic pressure on Entresto and Promacta
First nine months of 2025 showed 11% net sales growth and core EPS up 21%, driven by priority brands like Kisqali and Kesimpta
Acquisition of Avidity Biotechnology will bolster the neuroscience franchise with three late-stage programs, with merger expected to close in H1 2026
CEO expects the company to have essentially no tariff exposure by mid-2026
Named Competitors
Merck — Diversified pharmaceutical company with strong oncology and vaccines portfolio
Roche — Global biopharmaceutical leader in diagnostics and personalized healthcare
AbbVie — Pharmaceutical company focused on immunology, oncology, and virology
GSK — Global pharmaceutical leader in vaccines, specialty and general medicines
Recent Developments
(February 2026) Q4 2025 earnings beat on EPS but missed revenue expectations due to generic competition on Entresto and Promacta
(January 2026) FDA grants Breakthrough Therapy designation for ianalumab
(December 2025) Entered into agreement with U.S. government to reduce prices for innovative drugs while supporting domestic R&D investment
(December 2025) Announced agreement to acquire Avidity Biotechnology for neuromuscular disorders franchise expansion
Open the full interactive Novartis AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.